Glorioso and University of Pennsylvania microbiology professor Gary H. Cohen will share a $500,000, two-year grant to advance a vaccine for melanoma. Their research builds on previously successful results using a tumor-targeted, actively replicating herpes virus to infiltrate cancers and stimulate an immune system assault.
Glorioso calls the methodology a “heat-seeking missile that targets metastatic cancer for destruction.” Once the cancer is eliminated, the vaccine inserts an immunity barrier to protect against recurrence. Melanoma is among the most deadly cancers and this treatment offers new hope.
Glorioso, who founded the Pitt medical school’s Department of Microbiology and Molecular Genetics in 1989, is a pioneer in the design and application of herpes simplex virus gene vectors.